These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33470086)

  • 1. Factors associated with unfavourable treatment outcomes among people with rifampicin-resistant tuberculosis in Armenia, 2014-2017.
    Khachatryan L; Grigoryan R; Dadu A; Kumar AMV; Akopyan K; Dumchev K; Harutyunyan H; Matteelli A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
    Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
    BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.
    Makhmudova M; Maxsumova Z; Rajabzoda A; Makhmadov A; van den Hof S; Mirtskhulava V
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):331-336. PubMed ID: 30871664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015.
    Matambo R; Takarinda KC; Thekkur P; Sandy C; Mharakurwa S; Makoni T; Ncube R; Charambira K; Zishiri C; Ngwenya M; Nyathi S; Chiteka A; Chikaka E; Mutero-Munyati S
    PLoS One; 2020; 15(4):e0230848. PubMed ID: 32353043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with time to sputum culture conversion of rifampicin-resistant tuberculosis patients in Klaipeda, Lithuania in 2016-2019: a cohort study.
    Diktanas S; Korotych O; Sereda Y; Gozalov O; Rubcova O; Achar J
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013-2015: A retrospective cohort study.
    Chaves-Torres NM; Fadul S; Patiño J; Netto E
    PLoS One; 2021; 16(4):e0249565. PubMed ID: 33852619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with unfavourable treatment outcomes in people with HIV-associated tuberculosis in Armenia, 2015 to 2019.
    Gevorgyan L; Grigoryan R; Dumchev K; Akopyan K; Khachatryan A; Kabasakalyan E; Grigoryan T; Safaryan M; Avagyan V; Hasanova S; Matteelli A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.
    Woldeyohannes D; Assefa T; Aman R; Tekalegn Y; Hailemariam Z
    PLoS One; 2019; 14(10):e0224025. PubMed ID: 31665154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do catastrophic costs impact treatment outcomes in people with rifampicin-resistant tuberculosis in the Republic of Moldova?
    Plesca V; Ciobanu A; Sereda Y; Dadu A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis.
    Maier C; Chesov D; Schaub D; Kalsdorf B; Andres S; Friesen I; Reimann M; Lange C
    Clin Microbiol Infect; 2023 Jun; 29(6):751-757. PubMed ID: 36842637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.
    Habimana DS; Ngabonziza JCS; Migambi P; Mucyo-Habimana Y; Mutembayire G; Byukusenge F; Habiyambere I; Remera E; Mugwaneza P; Mwikarago IE; Mazarati JB; Turate I; Nsanzimana S; Decroo T; de Jong CB
    Am J Trop Med Hyg; 2021 May; 105(1):47-53. PubMed ID: 33999845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience.
    Liu CH; Li L; Chen Z; Wang Q; Hu YL; Zhu B; Woo PC
    PLoS One; 2011 Apr; 6(4):e19399. PubMed ID: 21559362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and factors associated with unfavourable treatment outcome among patients with rifampicin-resistant pulmonary tuberculosis in Yaoundé, Cameroon.
    Kuaban A; Balkissou AD; Ekongolo MCE; Nsounfon AW; Pefura-Yone EW; Kuaban C
    Pan Afr Med J; 2021; 38():229. PubMed ID: 34046134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with MDR-TB on domiciliary care in programmatic settings in Myanmar: Effect of a support package on preventing early deaths.
    Wai PP; Shewade HD; Kyaw NTT; Kyaw KWY; Thein S; Si Thu A; Oo MM; Htwe PS; Tun MMT; Win Maung HM; Soe KT; Aung ST
    PLoS One; 2017; 12(12):e0187223. PubMed ID: 29261669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
    Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
    Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.